MA27767A1 - Ligands des recepteurs de cannabinoides et leurs utilisations - Google Patents
Ligands des recepteurs de cannabinoides et leurs utilisationsInfo
- Publication number
- MA27767A1 MA27767A1 MA28566A MA28566A MA27767A1 MA 27767 A1 MA27767 A1 MA 27767A1 MA 28566 A MA28566 A MA 28566A MA 28566 A MA28566 A MA 28566A MA 27767 A1 MA27767 A1 MA 27767A1
- Authority
- MA
- Morocco
- Prior art keywords
- cannabinoid receptor
- receptor ligands
- ligands
- cannabinoid
- memo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
Ligands des récepteurs de cannabinoïdes et leurs utilisations Des composés de formules (I) et (II) qui jouent le rôle de ligands des récepteurs de cannabinoïdes et leurs utilisations dans le traitement de maladies en rapport avec la médiation des récepteurs de cannabinoïdes chez des animaux sont décrits dans le présent mémoire.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46483103P | 2003-04-23 | 2003-04-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27767A1 true MA27767A1 (fr) | 2006-02-01 |
Family
ID=33310962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28566A MA27767A1 (fr) | 2003-04-23 | 2005-10-21 | Ligands des recepteurs de cannabinoides et leurs utilisations |
Country Status (29)
Country | Link |
---|---|
US (3) | US7145012B2 (fr) |
EP (1) | EP1622909A1 (fr) |
JP (2) | JP3911285B2 (fr) |
KR (1) | KR20060006057A (fr) |
CN (1) | CN1777605A (fr) |
AP (1) | AP2005003426A0 (fr) |
AR (1) | AR044038A1 (fr) |
AU (1) | AU2004232553A1 (fr) |
BR (1) | BRPI0409701A (fr) |
CA (1) | CA2523364A1 (fr) |
CL (1) | CL2004000860A1 (fr) |
CO (1) | CO5640111A2 (fr) |
EA (1) | EA200501430A1 (fr) |
EC (1) | ECSP056116A (fr) |
GT (1) | GT200400078A (fr) |
IS (1) | IS8032A (fr) |
MA (1) | MA27767A1 (fr) |
MX (1) | MXPA05011361A (fr) |
NL (1) | NL1026028C2 (fr) |
NO (1) | NO20054407L (fr) |
OA (1) | OA13048A (fr) |
PA (1) | PA8601201A1 (fr) |
PE (1) | PE20050097A1 (fr) |
TN (1) | TNSN05271A1 (fr) |
TW (1) | TW200424207A (fr) |
UA (1) | UA79369C2 (fr) |
UY (1) | UY28277A1 (fr) |
WO (1) | WO2004094429A1 (fr) |
ZA (1) | ZA200507350B (fr) |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2294330T3 (es) * | 2002-08-02 | 2008-04-01 | MERCK & CO., INC. | Derivados de furo(2,3-b)piridina sustituidos. |
AU2003291342A1 (en) * | 2002-11-05 | 2004-06-07 | Arena Pharmaceuticals, Inc. | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof |
EP1603585A2 (fr) * | 2003-03-14 | 2005-12-14 | Bristol-Myers Squibb Company | Polynucleotide codant un nouveau variant de recepteur de hm74, hgprbmy74 couple a une proteine g humaine |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US20040214856A1 (en) * | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7141669B2 (en) * | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
BRPI0410289A (pt) * | 2003-05-07 | 2006-05-16 | Pfizer Prod Inc | ligantes do receptor de canabinóides e suas utilizações |
US7232823B2 (en) * | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
CN1805938B (zh) | 2003-06-17 | 2010-06-16 | 艾尼纳制药公司 | 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物 |
KR20060065584A (ko) * | 2003-06-20 | 2006-06-14 | 아레나 파마슈티칼스, 인크. | N-페닐-피페라진 유도체 및 5ht2c 수용체 관련 질환의예방 또는 치료 방법 |
US20050026983A1 (en) * | 2003-07-30 | 2005-02-03 | Pfizer Inc | Imidazole compounds and uses thereof |
PT1668014E (pt) * | 2003-09-17 | 2009-03-17 | Janssen Pharmaceutica Nv | Compostos heterocíclicos fundidos como moduladores do receptor de serotonina |
US7271189B2 (en) * | 2003-10-20 | 2007-09-18 | Solvay Pharmaceuticals, Inc. | 1H-imidazole derivatives as cannabinoid receptor modulators |
KR20060117952A (ko) * | 2003-10-20 | 2006-11-17 | 솔베이 파마슈티칼스 비. 브이 | 카나비노이드 수용체 조절제로서 1h-이미다졸 유도체 |
PE20050483A1 (es) | 2003-10-31 | 2005-08-25 | Arena Pharm Inc | Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas |
CA2544191A1 (fr) * | 2003-11-04 | 2005-05-26 | Merck & Co., Inc. | Derives de naphtyridinone substitues |
US7151097B2 (en) * | 2003-11-07 | 2006-12-19 | Pfizer Inc. | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof |
US7649002B2 (en) | 2004-02-04 | 2010-01-19 | Pfizer Inc | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists |
US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
BRPI0509207A (pt) * | 2004-03-24 | 2007-08-28 | Janssen Pharmaceutica Nv | moduladores canabinóides de tetraidro-indazol |
US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
US20060025448A1 (en) | 2004-07-22 | 2006-02-02 | Cadila Healthcare Limited | Hair growth stimulators |
US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
DK1814590T4 (da) * | 2004-11-01 | 2014-02-24 | Amylin Pharmaceuticals Llc | Behandling af obesitet og beslægtede sygdomme. |
EP2111859A1 (fr) * | 2004-12-23 | 2009-10-28 | Arena Pharmaceuticals, Inc. | compositions comprenant des modulateurs des recepteurs 5HT2C et leur utilisation |
PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
CN101189007A (zh) * | 2005-03-31 | 2008-05-28 | 詹森药业有限公司 | 四氢噻喃并吡唑大麻素调节剂 |
JP2008542255A (ja) * | 2005-05-27 | 2008-11-27 | ファイザー・プロダクツ・インク | 肥満症の治療または体重減量の維持のためのカンナビノイド−1受容体アンタゴニストおよびミクロソームトリグリセリド輸送タンパク質阻害物質の併用 |
US20090317376A1 (en) * | 2005-06-06 | 2009-12-24 | Georgetown University Medical School | Compositions And Methods For Lipo Modeling |
US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
WO2007055743A2 (fr) * | 2005-11-01 | 2007-05-18 | Amylin Pharmaceuticals, Inc. | Procédés pour traiter l'obésité et des troubles associés |
US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
US20090264470A1 (en) * | 2006-02-21 | 2009-10-22 | Bennett Teresa A | CB1 Antagonists and Inverse Agonists |
US8138188B2 (en) | 2006-02-23 | 2012-03-20 | Pfizer Inc. | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines |
JP4851546B2 (ja) * | 2006-03-10 | 2012-01-11 | ジェンリン ディスカバリー | 肥満治療に有用なカンナビノイド受容体アンタゴニスト/インバースアゴニスト |
US8722691B2 (en) * | 2006-03-30 | 2014-05-13 | Irm Llc | Azolopyrimidines as inhibitors of cannabinoid 1 activity |
KR20090047458A (ko) | 2006-08-08 | 2009-05-12 | 사노피-아벤티스 | 아릴아미노아릴-알킬-치환된 이미다졸리딘-2,4-디온, 이의 제조방법, 이들 화합물을 포함하는 약제 및 이의 용도 |
WO2008026219A2 (fr) * | 2006-09-01 | 2008-03-06 | Hetero Drugs Limited | Nouveaux polymorphes de rimonabant |
CA2669311C (fr) | 2006-11-13 | 2011-09-20 | Pfizer Products Inc. | Derives diaryle, dipyridinyle et aryl-pyridinyle et leurs utilisations |
CN101663262B (zh) | 2006-12-01 | 2014-03-26 | 百时美施贵宝公司 | 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物 |
WO2008083442A1 (fr) * | 2007-01-10 | 2008-07-17 | Brc Operations Pty Limited | Procédé pour la formulation de médicaments mixtes contre tdah |
WO2008115880A2 (fr) * | 2007-03-21 | 2008-09-25 | The Board Of Regents Of The University Of Texas System | Utilisation de leptine pour le traitement ou la prévention de la maladie de parkinson |
PE20090142A1 (es) * | 2007-04-11 | 2009-02-19 | Merck & Co Inc | Derivados de furo[2,3-b] piridina sustituidos como moduladores del receptor canabinoide-1 |
EP2170350B1 (fr) * | 2007-06-21 | 2013-09-11 | Cara Therapeutics, Inc. | Imidazohétérocycles substitués |
EP2025674A1 (fr) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament |
US8133904B2 (en) * | 2007-09-07 | 2012-03-13 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity |
WO2009041447A1 (fr) | 2007-09-28 | 2009-04-02 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique à 5 chaînons |
WO2009064298A1 (fr) * | 2007-11-14 | 2009-05-22 | Amylin Pharmaceuticals, Inc. | Procédés de traitement de l'obésité et de maladies et de troubles associés à l'obésité |
EP2242745A1 (fr) * | 2008-02-07 | 2010-10-27 | Sanofi-Aventis | Nouvelles imidazolidines substituées par un phényle, procédé de production, médicaments contenant ces composés et leur utilisation |
WO2009111004A1 (fr) * | 2008-03-04 | 2009-09-11 | Arena Pharmaceuticals, Inc. | Procédés de préparation d'intermédiaires se rapportant à l'agoniste 5-ht<sb>2c</sb> (r)-8-chloro-1-méthyl-2,3,4,5-tétrahydro-1h-3-benzazepine |
EP2116618A1 (fr) | 2008-05-09 | 2009-11-11 | Agency for Science, Technology And Research | Diagnostic et traitement de la maladie de Kawasaki |
US8470841B2 (en) | 2008-07-09 | 2013-06-25 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
KR101280786B1 (ko) | 2008-08-06 | 2013-07-05 | 화이자 리미티드 | 멜라노코르틴 4 작용제로서 다이아제핀 및 다이아조칸 화합물 |
CN102272135A (zh) * | 2008-10-08 | 2011-12-07 | 百时美施贵宝公司 | 唑并吡咯酮黑色素浓集激素受体-1拮抗剂 |
JO2870B1 (en) | 2008-11-13 | 2015-03-15 | ميرك شارب اند دوهم كورب | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes |
WO2010068601A1 (fr) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant |
RU2012111354A (ru) | 2009-08-26 | 2013-10-10 | Санофи | Новые кристаллические гидраты фторгликозидов, содержащие их фармацевтические препараты и их использование |
EP2480082A4 (fr) | 2009-09-25 | 2014-01-15 | Merck Sharp & Dohme | Aminopipéridines substituées utilisées en tant qu'inhibiteurs de la dipeptidyl peptidase-iv dans le cadre du traitement du diabète |
WO2011153206A1 (fr) | 2010-06-02 | 2011-12-08 | Arena Pharmaceuticals, Inc. | Procédés pour la préparation d'agonistes du récepteur 5-ht2c |
EP2582709B1 (fr) | 2010-06-18 | 2018-01-24 | Sanofi | Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases |
WO2012030957A2 (fr) | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | Sels non hygroscopiques d'agonistes de 5-ht2c |
SG188365A1 (en) | 2010-09-01 | 2013-04-30 | Arena Pharm Inc | Administration of lorcaserin to individuals with renal impairment |
KR20130138770A (ko) | 2010-09-01 | 2013-12-19 | 아레나 파마슈티칼스, 인크. | 광학적으로 활성 산을 갖는 로르카세린의 염 |
CN103189053A (zh) | 2010-09-01 | 2013-07-03 | 艾尼纳制药公司 | 用于体重控制的5-ht2c激动剂的调节释放剂型 |
CA2726085A1 (fr) * | 2010-12-20 | 2012-06-20 | Bernard Le Foll | Utilisateur de cannabis et autres composes contenus pour le traitement de l'obesite |
WO2012120056A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
EP2683699B1 (fr) | 2011-03-08 | 2015-06-24 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
US8809325B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
WO2012120050A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, médicaments contenant ces composés et leur utilisation |
WO2012120057A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation |
WO2012120058A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés d'oxathiazine substitués par des groupes benzyle ou hétérométhylène, leur procédé de production, leur utilisation comme médicament ainsi que produits pharmaceutiques les contenant et leur utilisation |
WO2012120054A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US20120282255A1 (en) * | 2011-04-07 | 2012-11-08 | Greg Plucinski | Methods and compositions for the treatment of alcoholism and alcohol dependence |
JO3357B1 (ar) * | 2012-01-26 | 2019-03-13 | Novartis Ag | مركبات إيميدازوبيروليدينون |
WO2013175417A1 (fr) | 2012-05-24 | 2013-11-28 | Novartis Ag | Composés pyrrolopyrrolidinones |
CA2882127A1 (fr) * | 2012-08-16 | 2014-02-20 | Janssen Pharmaceutica Nv | Pyrrolopyrazoles comme bloqueurs de canal calcique de type n |
KR20150042269A (ko) | 2012-08-16 | 2015-04-20 | 얀센 파마슈티카 엔.브이. | N형 칼슘 채널 차단제로서의 치환된 피라졸 |
US20150297610A1 (en) | 2012-10-09 | 2015-10-22 | Arena Pharmaceuticals, Inc. | Method of weight management |
EP2948453B1 (fr) | 2013-01-22 | 2017-08-02 | Novartis AG | Composés pyrazolo[3,4-d]pyrimidinone utilisés en tant qu'inhibiteurs de l'interaction p53/mdm2 |
US9403827B2 (en) | 2013-01-22 | 2016-08-02 | Novartis Ag | Substituted purinone compounds |
US9890166B2 (en) | 2013-05-27 | 2018-02-13 | Novartis Ag | Imidazopyrrolidine derivatives and their use in the treatment of disease |
US9624247B2 (en) | 2013-05-28 | 2017-04-18 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease |
PT3004112T (pt) | 2013-05-28 | 2017-12-11 | Novartis Ag | Derivados de pirazolo-pirrolidin-4-ona e sua utilização no tratamento de doença |
US9453002B2 (en) | 2013-08-16 | 2016-09-27 | Janssen Pharmaceutica Nv | Substituted imidazoles as N-type calcium channel blockers |
MX2016006667A (es) | 2013-11-21 | 2016-07-26 | Novartis Ag | Derivados de pirrolo-pirrolona y su uso como inhibidores. |
AU2018277523B2 (en) | 2017-05-31 | 2022-06-23 | Chemocentryx, Inc. | 5-5 fused rings as C5a inhibitors |
CN110997674B (zh) | 2017-05-31 | 2022-12-20 | 凯莫森特里克斯股份有限公司 | 作为C5a抑制剂的6-5稠合环类 |
IL275516B2 (en) * | 2017-12-22 | 2023-12-01 | Chemocentryx Inc | Ring compounds fused at the 5- and 6-position are diaryl-converted as C5AR inhibitors |
US10828285B2 (en) * | 2017-12-22 | 2020-11-10 | Chemocentryx, Inc. | Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors |
SG11202009588PA (en) * | 2018-04-02 | 2020-10-29 | Chemocentryx Inc | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS |
US10897925B2 (en) | 2018-07-27 | 2021-01-26 | Joseph Pandolfino | Articles and formulations for smoking products and vaporizers |
US20200035118A1 (en) | 2018-07-27 | 2020-01-30 | Joseph Pandolfino | Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes |
US11504416B2 (en) | 2018-09-04 | 2022-11-22 | Paw Power, Inc. | Formulation with cannabinoids |
CA3156100A1 (fr) * | 2019-09-30 | 2021-04-08 | Janssen Pharmaceutica Nv | Ligands mgl pet radiomarques |
CN117460731A (zh) * | 2021-06-11 | 2024-01-26 | 劲方医药科技(上海)有限公司 | 杂环内酰胺类化合物,其制法与医药上的用途 |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US224970A (en) * | 1880-02-24 | Hand-tool for dressing millstones | ||
US3365459A (en) * | 1964-09-08 | 1968-01-23 | Ciba Geigy Corp | Certain tetrahydro pyrazolo-pyridine and pyrazolo-piperidine derivatives |
US3340269A (en) * | 1964-09-08 | 1967-09-05 | Ciba Geigy Corp | 1-substituted 4-acyl-2, 3-dioxo-piperidine |
US3423414A (en) | 1966-01-13 | 1969-01-21 | Ciba Geigy Corp | Pyrazolopyridines |
US3526633A (en) * | 1968-03-06 | 1970-09-01 | American Cyanamid Co | Substituted 2,4,5,6-tetrahydropyrrolo(3,4-c)pyrazoles |
DE3204713A1 (de) * | 1982-02-11 | 1983-08-18 | Basf Ag, 6700 Ludwigshafen | Aminopyrazolverbindungen |
SU1069387A1 (ru) * | 1982-07-01 | 1985-11-30 | Институт физико-органической химии и углехимии АН УССР | Дигидрохлорид 5-/ @ -( @ -анизил)- @ -оксиэтил/ 2-(3,4-диметоксифенил)-1-метил-4,5,6,7-тетрагидроимидазо(4,5- @ )пиридина,обладающий спазмолитическим действием |
GB8613591D0 (en) | 1986-06-04 | 1986-07-09 | Roussel Lab Ltd | Chemical compounds |
DE3775527D1 (de) * | 1986-10-22 | 1992-02-06 | Ciba Geigy Ag | 1,5-diphenylpyrazol-3-carbonsaeurederivate zum schuetzen von kulturpflanzen. |
AU611437B2 (en) | 1987-05-29 | 1991-06-13 | Ortho Pharmaceutical Corporation | Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-n-hydroxypropanamides and method for synthesizing the same |
PH27357A (en) * | 1989-09-22 | 1993-06-21 | Fujisawa Pharmaceutical Co | Pyrazole derivatives and pharmaceutical compositions comprising the same |
FR2665898B1 (fr) * | 1990-08-20 | 1994-03-11 | Sanofi | Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
CH681806A5 (fr) | 1991-03-19 | 1993-05-28 | Ciba Geigy Ag | |
FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
PL312426A1 (en) | 1993-07-06 | 1996-04-29 | Pfizer | Bicyclic tetrahydropyrazolepyridines |
FR2714057B1 (fr) * | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
US5508300A (en) * | 1994-01-14 | 1996-04-16 | Pfizer Inc. | Dihydro pyrazolopyrroles, compositions and use |
US5596106A (en) | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
FR2741621B1 (fr) | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
FR2742148B1 (fr) | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
EP0971588B1 (fr) | 1997-01-21 | 2004-03-17 | Smithkline Beecham Corporation | Nouveaux modulateurs de recepteurs de cannabinoides |
FR2758723B1 (fr) | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
FR2761266B1 (fr) * | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates |
WO1999046267A1 (fr) | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulateurs de proteine tyrosine phosphatases (ptpases) |
FR2783246B1 (fr) | 1998-09-11 | 2000-11-17 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les medicaments les contenant |
IL141769A0 (en) | 1998-09-11 | 2002-03-10 | Aventis Pharma Sa | Azetidine derivatives, preparation and medicines containing them |
FR2789079B3 (fr) | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
EP1173438A1 (fr) | 1999-04-16 | 2002-01-23 | Novo Nordisk A/S | Imidazoles substitues, leur preparation et utilisation |
FR2799124B1 (fr) | 1999-10-01 | 2004-08-13 | Sanofi Synthelabo | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
AU1095101A (en) | 1999-10-18 | 2001-04-30 | University Of Connecticut, The | Cannabimimetic indole derivatives |
AU780572B2 (en) | 1999-10-18 | 2005-04-07 | University Of Connecticut, The | Pyrazole derivatives as cannabinoid receptor antagonists |
WO2003020217A2 (fr) | 2001-08-31 | 2003-03-13 | University Of Connecticut | Nouveaux analogues de pyrazole agissant sur les recepteurs cannabinoides |
FR2800375B1 (fr) | 1999-11-03 | 2004-07-23 | Sanofi Synthelabo | Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
FR2800372B1 (fr) | 1999-11-03 | 2001-12-07 | Sanofi Synthelabo | Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant |
CA2363274A1 (fr) | 1999-12-27 | 2001-07-05 | Japan Tobacco Inc. | Composes a noyaux fusionnes et leurs utilisations comme medicaments contre l'hepatite c |
FR2804604B1 (fr) | 2000-02-09 | 2005-05-27 | Sanofi Synthelabo | Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac |
WO2001058869A2 (fr) | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Modulateurs de recepteurs aux cannabinoides, leurs procedes de preparation et utilisations de modulateurs de recepteurs aux cannabinoides pour le traitement de maladies respiratoires et non respiratoires |
US6355631B1 (en) | 2000-03-03 | 2002-03-12 | Aventis Pharma S.A. | Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation |
US6479479B2 (en) * | 2000-03-03 | 2002-11-12 | Aventis Pharma S.A. | Azetidine derivatives, their preparation and pharmaceutical compositions containing them |
US6566356B2 (en) * | 2000-03-03 | 2003-05-20 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation |
JP2004500401A (ja) * | 2000-03-23 | 2004-01-08 | ソルベイ・フアーマシユーチカルズ・ベー・ブイ | Cb1−拮抗活性を有する4,5−ジヒドロ−1h−ピラゾール誘導体 |
FR2809621B1 (fr) | 2000-05-12 | 2002-09-06 | Sanofi Synthelabo | Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles comme antidiarrheiques |
US20020019421A1 (en) * | 2000-07-05 | 2002-02-14 | Roni Biberman | Compositions and therapy for substance addiction |
US20020091114A1 (en) * | 2000-10-04 | 2002-07-11 | Odile Piot-Grosjean | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity |
EP1354884B1 (fr) | 2000-12-28 | 2007-10-10 | Ono Pharmaceutical Co., Ltd. | Compose cyclopenta[d]pyrazolo[1,5-a]pyrimidine comme antagoniste du recepteur du crf |
SK287592B6 (sk) | 2001-03-22 | 2011-03-04 | Solvay Pharmaceuticals B. V. | 4,5-Dihydro-1H-pyrazolové deriváty, ktoré majú CB1-antagonistickú účinnosť, spôsob ich prípravy a použitie |
ITMI20011483A1 (it) | 2001-07-11 | 2003-01-11 | Res & Innovation Soc Coop A R | Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi |
WO2003007945A1 (fr) | 2001-07-20 | 2003-01-30 | Boehringer Ingelheim (Canada) Ltd. | Inhibiteurs de polymerase virale |
WO2003007887A2 (fr) | 2001-07-20 | 2003-01-30 | Merck & Co., Inc. | Imidazoles substitues servant de modulateurs de recepteurs de cannabinoides |
FR2829027A1 (fr) | 2001-08-29 | 2003-03-07 | Aventis Pharma Sa | Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson |
FR2829028B1 (fr) | 2001-08-29 | 2004-12-17 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de |
KR100950430B1 (ko) | 2001-09-21 | 2010-04-02 | 솔베이 파마슈티칼스 비. 브이 | 효력있는 cb1-길항 작용을 가지는4,5-디하이드로-1h-피라졸 유도체 |
TWI231757B (en) | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
HUP0401567A3 (en) | 2001-09-21 | 2005-06-28 | Solvay Pharm Bv | Novel 4,5-dyhydro-1h-pyrazole derivatives having cb1-antagonistic activity, their use and pharmaceutical compositions containing them |
US6509367B1 (en) | 2001-09-22 | 2003-01-21 | Virginia Commonwealth University | Pyrazole cannabinoid agonist and antagonists |
HN2002000266A (es) | 2001-09-24 | 2003-11-16 | Bayer Corp | Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad. |
JP2005532982A (ja) | 2001-09-24 | 2005-11-04 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 肥満の処置のためのピロール誘導体の製造及び使用 |
EP1432708B1 (fr) | 2001-09-24 | 2005-11-30 | Bayer Pharmaceuticals Corporation | Preparation et utilisation de derives de la 1,5,6,7-tetrahydropyrrolo 3,2-c]pyridine pour le traitement de l'obesite |
SE0104332D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
SE0104330D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
US20030139386A1 (en) * | 2001-12-21 | 2003-07-24 | Sophie Cote | Pharmaceutical compositions based on azetidine derivatives |
AU2003219934A1 (en) | 2002-03-06 | 2003-09-22 | Merck And Co., Inc. | Method of treatment or prevention of obesity |
EP1496838B1 (fr) | 2002-03-12 | 2010-11-03 | Merck Sharp & Dohme Corp. | Amides substitues |
AR038966A1 (es) | 2002-03-18 | 2005-02-02 | Solvay Pharm Bv | Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1 |
JP2005528366A (ja) | 2002-03-26 | 2005-09-22 | メルク エンド カムパニー インコーポレーテッド | カンナビノイド受容体モジュレータとしてのスピロ環式アミド |
ES2192494B1 (es) | 2002-03-27 | 2005-02-16 | Consejo Superior De Investigaciones Cientificas | Derivados de 1,2,4-triazol con propiedades cannabinoides. |
FR2837706A1 (fr) | 2002-03-28 | 2003-10-03 | Sanofi Synthelabo | Utilisation d'un antagoniste des recepteurs aux cannabinoides cb1 pour la preparation de medicaments utiles pour traiter les dysfonctionnements sexuels et/ou ameliorer les performances sexuelles |
US7271266B2 (en) | 2002-03-28 | 2007-09-18 | Merck & Co., Inc. | Substituted 2,3-diphenyl pyridines |
EP1494997A4 (fr) | 2002-04-05 | 2007-04-11 | Merck & Co Inc | Arylamides substituee |
FR2838439B1 (fr) | 2002-04-11 | 2005-05-20 | Sanofi Synthelabo | Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant |
US7667053B2 (en) | 2002-04-12 | 2010-02-23 | Merck & Co., Inc. | Bicyclic amides |
US6825209B2 (en) * | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
JP2005529919A (ja) | 2002-05-10 | 2005-10-06 | スミスクライン ビーチャム コーポレーション | 治療用化合物 |
DE60325243D1 (de) | 2002-08-02 | 2009-01-22 | Warsaw Orthopedic Inc | Systeme und techniken zur beleuchtung eines operationsraums |
WO2004035566A1 (fr) * | 2002-10-18 | 2004-04-29 | Pfizer Products Inc. | Ligands des recepteurs des cannabinoides et applications de ceux-ci |
US7129239B2 (en) * | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US20040214856A1 (en) | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
-
2004
- 2004-04-12 US US10/823,107 patent/US7145012B2/en not_active Expired - Fee Related
- 2004-04-20 AU AU2004232553A patent/AU2004232553A1/en not_active Abandoned
- 2004-04-20 CA CA002523364A patent/CA2523364A1/fr not_active Abandoned
- 2004-04-20 OA OA1200500292A patent/OA13048A/en unknown
- 2004-04-20 AP AP2005003426A patent/AP2005003426A0/xx unknown
- 2004-04-20 WO PCT/IB2004/001482 patent/WO2004094429A1/fr active Application Filing
- 2004-04-20 KR KR1020057020095A patent/KR20060006057A/ko not_active Application Discontinuation
- 2004-04-20 CN CNA2004800106829A patent/CN1777605A/zh active Pending
- 2004-04-20 MX MXPA05011361A patent/MXPA05011361A/es unknown
- 2004-04-20 UA UAA200509932A patent/UA79369C2/uk unknown
- 2004-04-20 EP EP04728383A patent/EP1622909A1/fr not_active Withdrawn
- 2004-04-20 JP JP2006506605A patent/JP3911285B2/ja not_active Expired - Fee Related
- 2004-04-20 EA EA200501430A patent/EA200501430A1/ru unknown
- 2004-04-20 PE PE2004000388A patent/PE20050097A1/es not_active Application Discontinuation
- 2004-04-20 BR BRPI0409701-7A patent/BRPI0409701A/pt not_active IP Right Cessation
- 2004-04-21 AR ARP040101340A patent/AR044038A1/es unknown
- 2004-04-21 UY UY28277A patent/UY28277A1/es not_active Application Discontinuation
- 2004-04-21 GT GT200400078A patent/GT200400078A/es unknown
- 2004-04-22 PA PA20048601201A patent/PA8601201A1/es unknown
- 2004-04-22 CL CL200400860A patent/CL2004000860A1/es unknown
- 2004-04-22 TW TW093111250A patent/TW200424207A/zh unknown
- 2004-04-23 NL NL1026028A patent/NL1026028C2/nl not_active IP Right Cessation
-
2005
- 2005-09-13 ZA ZA200507350A patent/ZA200507350B/xx unknown
- 2005-09-15 IS IS8032A patent/IS8032A/is unknown
- 2005-09-22 NO NO20054407A patent/NO20054407L/no not_active Application Discontinuation
- 2005-10-21 MA MA28566A patent/MA27767A1/fr unknown
- 2005-10-21 CO CO05106975A patent/CO5640111A2/es not_active Application Discontinuation
- 2005-10-21 EC EC2005006116A patent/ECSP056116A/es unknown
- 2005-10-21 TN TNP2005000271A patent/TNSN05271A1/fr unknown
-
2006
- 2006-05-12 US US11/433,848 patent/US7241788B2/en not_active Expired - Fee Related
- 2006-05-12 US US11/433,171 patent/US7230024B2/en not_active Expired - Fee Related
- 2006-10-18 JP JP2006283916A patent/JP2007084553A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27767A1 (fr) | Ligands des recepteurs de cannabinoides et leurs utilisations | |
MA27766A1 (fr) | Ligands de recepteurs de cannabinoides et leurs utilisations | |
MA27853A1 (fr) | LIGANDS DES RECEPTEURS DE CANNABINOiDES ET LEURS UTILISATIONS | |
TNSN05121A1 (fr) | Purines et leurs utilisations comme ligands des recepteurs de cannabinoides | |
TNSN06129A1 (fr) | Derives de pyrazolyle et d'imidazolyle bicycliques et leurs utilisations | |
TNSN05190A1 (fr) | DERIVES DE PYRAZOLO [1,5-a][1,3,5] TRIAZINE SERVANT DE LIGANDS DES RECEPTEURS DE CANNABINOIDES | |
TNSN03142A1 (fr) | Ligands des recepteurs de 5-ht et leurs utilisations | |
HRP20040684B1 (hr) | Spojevi 2,4-pirimidindiamina i njihova upotreba | |
MXPA05007938A (es) | Ligandos de receptores de cannabinoides y usos de los mismos. | |
MXPA05010164A (es) | Ligandos de receptores de canabinoides y sus usos. | |
MXPA05011922A (es) | Ligandos del receptor de cannabinoides y sus usos. | |
MXPA05011362A (es) | Ligandos de receptor cannabinoide y usos de los mismos. | |
ATE526991T1 (de) | Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen | |
FR16C0028I2 (fr) | Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques | |
MA28935B1 (fr) | Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite | |
MXPA05013282A (es) | Derivados de pirimidina como ligandos del receptor de cannabinoides. | |
MA29354B1 (fr) | Derives de cyclopentapyridine et tetrahydroquinoleine. | |
EA200700934A1 (ru) | Производные пиримидина и их применение в качестве модуляторов cb2 | |
DE60327999D1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
MA30485B1 (fr) | Aminothiazoles et leurs utilisations | |
GT200400231A (es) | Compuestos de sulfoniltetrahidro-3h-benzo(e)indol-8-amina como ligandos de la 5-hidroxitriptamina-6. | |
NO20060420L (no) | 2-aminobenzoylderivater | |
FR2842422B1 (fr) | Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations | |
ATE396726T1 (de) | Benzothiazole derivate und ihre anwendung in der behandlung von adenosine a2a rezeptor vermittelte krankheiten | |
ATE423780T1 (de) | Makrozyclen zur behandlung von krebserkrankungen |